# Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

> **NCT03999515** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 3 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Double-Negative Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Enzalutamide
- **DRUG:** Erdafitinib

## Key facts

- **NCT ID:** NCT03999515
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-27
- **Primary completion:** 2021-06-06
- **Final completion:** 2021-06-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03999515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03999515, "Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03999515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*